Resolvin D1 polarizes primary human macrophages toward a proresolution phenotype through GPR32

Journal of Immunology

Volumn 196, Issue 8, 2016, Pages 3429-3437

  Schmid, Mattia ^a,b   Gemperle, Claudio ^a,b   Rimann, Nicole ^a,b   Hersberger, Martin ^a,b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMERIN; CHEMOATTRACTANT; FMLF PROTEIN; GPR32 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MEMBRANE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RESOLVIN D1; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR; GPR32 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MICROORGANISM; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; MIGRATION INHIBITION; PHENOTYPE; RNA INTERFERENCE;

ANTI-INFLAMMATORY AGENTS; CELL MIGRATION INHIBITION; CELLS, CULTURED; CHEMOTAXIS; DOCOSAHEXAENOIC ACIDS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MACROPHAGES; PHAGOCYTOSIS; PHENOTYPE; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84974822768     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501701     Document Type: Article

References (44)

1. Silva, M. T. 2010. When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J. Leukoc. Biol. 87: 93-106.
2. Gordon, S., and P. R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5: 953-964.
3. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737.
4. Murray, P. J., J. E. Allen, S. K. Biswas, E. A. Fisher, D. W. Gilroy, S. Goerdt, S. Gordon, J. A. Hamilton, L. B. Ivashkiv, T. Lawrence, et al. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41: 14-20.
5. Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122: 787-795.
6. Gordon, S., and F. O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
7. Bystrom, J., I. Evans, J. Newson, M. Stables, I. Toor, N. van Rooijen, M. Crawford, P. Colville-Nash, S. Farrow, and D. W. Gilroy. 2008. Resolutionphase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 112: 4117-4127.
8. Porcheray, F., S. Viaud, A. C. Rimaniol, C. Léone, B. Samah, N. Dereuddre-Bosquet, D. Dormont, and G. Gras. 2005. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 142: 481-489.
9. Gratchev, A., J. Kzhyshkowska, K. Köthe, I. Muller-Molinet, S. Kannookadan, J. Utikal, and S. Goerdt. 2006. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 211: 473-486.
10. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R. L. Moussignac. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037.
11. Kasuga, K., R. Yang, T. F. Porter, N. Agrawal, N. A. Petasis, D. Irimia, M. Toner, and C. N. Serhan. 2008. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181: 8677-8687.
12. Naccache, P. H. 1987. Signals for actin polymerization in neutrophils. Biomed. Pharmacother. 41: 297-304.
13. Merched, A. J., K. Ko, K. H. Gotlinger, C. N. Serhan, and L. Chan. 2008. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22: 3595-3606.
14. Park, C. K., Z. Z. Xu, T. Liu, N. Lü, C. N. Serhan, and R. R. Ji. 2011. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/ A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J. Neurosci. 31: 18433-18438.
15. Xu, Z. Z., L. Zhang, T. Liu, J. Y. Park, T. Berta, R. Yang, C. N. Serhan, and R. R. Ji. 2010. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16: 592-597, 591p following 597. doi:10.1038/ nm.2123
16. Wang, B., X. Gong, J. Y. Wan, L. Zhang, Z. Zhang, H. Z. Li, and S. Min. 2011. Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm. Pharmacol. Ther. 24: 434-441.
17. Bento, A. F., R. F. Claudino, R. C. Dutra, R. Marcon, and J. B. Calixto. 2011. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J. Immunol. 187: 1957-1969.
18. Clària, J., J. Dalli, S. Yacoubian, F. Gao, and C. N. Serhan. 2012. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J. Immunol. 189: 2597-2605.
19. Hellmann, J., Y. Tang, M. Kosuri, A. Bhatnagar, and M. Spite. 2011. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 25: 2399-2407.
20. Krishnamoorthy, S., A. Recchiuti, N. Chiang, S. Yacoubian, C. H. Lee, R. Yang, N. A. Petasis, and C. N. Serhan. 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107: 1660-1665.
21. Norling, L. V., J. Dalli, R. J. Flower, C. N. Serhan, and M. Perretti. 2012. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler. Thromb. Vasc. Biol. 32: 1970-1978.
22. Waechter, V., M. Schmid, M. Herova, A. Weber, V. Günther, J. Marti-Jaun, S. Wüst, M. Rösinger, C. Gemperle, and M. Hersberger. 2012. Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human monocytes and macrophages. J. Immunol. 188: 1856-1867.
23. Sun, Y. P., S. F. Oh, J. Uddin, R. Yang, K. Gotlinger, E. Campbell, S. P. Colgan, N. A. Petasis, and C. N. Serhan. 2007. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282: 9323-9334.
24. Weiss, G. A., H. Troxler, G. Klinke, D. Rogler, C. Braegger, and M. Hersberger. 2013. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis. 12: 89.
25. Gemperle, C., M. Schmid, M. Herova, J. Marti-Jaun, S. J. Wuest, C. Loretz, and M. Hersberger. 2012. Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages. PLoS One 7: e50195.
26. Troegeler, A., C. Lastrucci, C. Duval, A. Tanne, C. Cougoule, I. Maridonneau-Parini, O. Neyrolles, and G. Lugo-Villarino. 2014. An efficient siRNA-mediated gene silencing in primary human monocytes, dendritic cells and macrophages. Immunol. Cell Biol. 92: 699-708.
27. Herová, M., M. Schmid, C. Gemperle, and M. Hersberger. 2015. ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages. J. Immunol. 194: 2330-2337.
28. Rubartelli, A., A. Bajetto, G. Allavena, F. Cozzolino, and R. Sitia. 1993. Posttranslational regulation of interleukin 1 beta secretion. Cytokine 5: 117-124.
29. Stables, M. J., S. Shah, E. B. Camon, R. C. Lovering, J. Newson, J. Bystrom, S. Farrow, and D. W. Gilroy. 2011. Transcriptomic analyses of murine resolution-phase macrophages. Blood 118: e192-e208.
30. Serhan, C. N. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92-101.
31. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27: 451-483.
32. Benoit, M., B. Desnues, and J. L. Mege. 2008. Macrophage polarization in bacterial infections. J. Immunol. 181: 3733-3739.
33. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896.
34. Schif-Zuck, S., N. Gross, S. Assi, R. Rostoker, C. N. Serhan, and A. Ariel. 2011. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41: 366-379.
35. Titos, E., B. Rius, A. González-Périz, C. López-Vicario, E. Morán-Salvador, M. Martínez-Clemente, V. Arroyo, and J. Clària. 2011. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 187: 5408-5418.
36. Takano, T., S. Fiore, J. F. Maddox, H. R. Brady, N. A. Petasis, and C. N. Serhan. 1997. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185: 1693-1704.
37. Chiang, N., T. Takano, M. Arita, S. Watanabe, and C. N. Serhan. 2003. A novel rat lipoxin A4 receptor that is conserved in structure and function. Br. J. Pharmacol. 139: 89-98.
38. Devchand, P. R., M. Arita, S. Hong, G. Bannenberg, R. L. Moussignac, K. Gronert, and C. N. Serhan. 2003. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17: 652-659.
39. Dufton, N., R. Hannon, V. Brancaleone, J. Dalli, H. B. Patel, M. Gray, F. D'Acquisto, J. C. Buckingham, M. Perretti, and R. J. Flower. 2010. Antiinflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184: 2611-2619.
40. Machado, F. S., J. E. Johndrow, L. Esper, A. Dias, A. Bafica, C. N. Serhan, and J. Aliberti. 2006. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12: 330-334.
41. Russell, R., I. Gori, C. Pellegrini, R. Kumar, C. Achtari, and G. O. Canny. 2011. Lipoxin A4 is a novel estrogen receptor modulator. FASEB J. 25: 4326-4337.
42. Jones, C. N., J. Dalli, L. Dimisko, E. Wong, C. N. Serhan, and D. Irimia. 2012. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc. Natl. Acad. Sci. USA 109: 20560-20565.
43. Kasama, T., R. M. Strieter, T. J. Standiford, M. D. Burdick, and S. L. Kunkel. 1993. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. J. Exp. Med. 178: 63-72.
44. Maddox, J. F., M. Hachicha, T. Takano, N. A. Petasis, V. V. Fokin, and C. N. Serhan. 1997. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272: 6972-6978.